Article

Fibrin glue in amniotic membrane transplant helps repair symptomatic conjunctivochalasis

Lisbon, Portugal - When treating conjunctivochalasis, which is characterized by dissolution of Tenon’s membrane, replacement by amnionic membrane held in place by fibrin glue reinforces the membrane, according to Thomas John, MD, who reported his findings Sunday at the European Society of Cataract and Refractive Surgeons meeting. Dr. John is from Loyola University at Chicago, Maywood, IL, United States.

Lisbon, Portugal - When treating conjunctivochalasis, which is characterized by dissolution of Tenon’s membrane, replacement by amnionic membrane held in place by fibrin glue reinforces the membrane, according to Thomas John, MD, who reported his findings Sunday at the European Society of Cataract and Refractive Surgeons meeting. Dr. John is from Loyola University at Chicago, Maywood, IL, United States.

Dr. John et al. used this technique in 24 eyes of 16 patients (10 women, 6 men; average age, 63 years). Eight of the patients were treated bilaterally. Preoperatively, their symptoms included a foreign body sensation, redness, inflammation, and tearing.

The fibrin glue (Baxter) has two components: thrombin and fibrinogen. Dr. John explained that he prefers to apply the components separately to achieve better control. During the procedure, the amniotic membrane is applied stromal side down, glued into place, and the conjunctival opening is sealed with glue.

After surgery, he reported, “the patients had dramatic relief of symptoms and the fibrin glue effectively anchored the amniotic membrane in the space between conjunctiva and Tenon’s membrane.”

He also noted that use of the glue results in a shorter surgical time compared with the standard surgery and increases the ease of postoperative healing.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.